Health
Novo Nordisk Partners With MIT-Backed Startup to Develop Oral Obesity Drugs
Novo Nordisk has struck a deal with Vivtex, a biotech co-founded by MIT professor Robert Langer, to develop oral versions of obesity and diabetes treatments. The partnership could eliminate the need for weekly injections that have defined the GLP-1 drug revolution.
Key Takeaways
- Novo Nordisk deals with Vivtex to develop oral alternatives to injectable obesity and diabetes drugs
- Vivtex was co-founded by MIT's Robert Langer, also a Moderna co-founder
- Oral delivery could massively expand the GLP-1 market beyond injection-averse patients
- Competes with Eli Lilly and others racing to develop pill-form GLP-1 treatments
DE
DT Editorial AI··via statnews.com